Background: Integrase strand transfer inhibitors (INSTIs) are recommended by international guidelines as firstline therapy in antiretroviral-naive and -experienced HIV-1-infected patients.
Introduction
Integrase strand transfer inhibitors (INSTIs), which act by inhibiting the HIV integrase enzyme from inserting viral DNA genome into the host cell's chromatin, are the most recent class of antiretroviral (ARV) drugs approved for treatment of HIV-infected individuals.
Current practice guidelines (US Department of Health and Human
Services, European AIDS Clinical Society and French guidelines) recommend the use of this class as first-line therapy in ARV-naive and -experienced patients. [1] [2] [3] However, some studies have shown selection of raltegravirand elvitegravir-resistant strains in patients experiencing . [4] [5] [6] The most frequent primary resistance pathways observed in vitro, in vivo and in clinical trials are Y143R, Q148H/R/K and N155H for raltegravir, and T66I, E92Q, Q148H/K/R and N155H for elvitegravir. 7, 8 Dolutegravir is known to create a higher genetic barrier to resistance, and thus an accumulation of multiple mutations, possibly selected under raltegravir or elvitegravir pressure, is required to reduce susceptibility to dolutegravir. 9, 10 In phenotypic studies, susceptibility to dolutegravir is reduced in the presence of Q148H/K/R mutations especially when combined with L74I, E138A/K/T, G140A/C/S or N155H. 7, 11 However, several studies have shown that raltegravir failures were also observed in the absence of detectable resistance. For example, a Spanish cohort treated with raltegravir showed that the viruses of 50/89 (56%) patients lacked emerging mutations on the integrase gene at failure. 12 In a clinical setting, a study by Fourati et al. 13 on 502 patients failing a raltegravir-based regimen showed a selection at failure of resistance mutations to the INSTI class in only 39% of cases. In clinical practice, VF and the emergence of resistance mutations have rarely been reported in patients receiving dolutegravir-based therapy. 14, 15 It should be noted that studies such as these are often performed by traditional Sanger sequencing and thus may underestimate the prevalence of drug-resistant variants. Therefore, our first objective was to investigate the prevalence at failure of resistant variants in patients failing an INSTI-based regimen by ultra-deep sequencing (UDS). Furthermore, to better document the VF under INSTI treatment, pharmacological determinations were performed concomitantly to investigate treatment adherence in patients failing INSTI-based regimen. Our second objective was to investigate the clinical impact of baseline minority resistant variants (MiRVs) on an INSTI-based regimen, one of the major questions still under discussion. Indeed, the detection of pre-existing MiRVs was correlated with a higher risk of VF for the first generation of NNRTIs, 16, 17 while few other studies have failed to establish this association for NRTIs and PIs. [18] [19] [20] For INSTIs, several small-scale studies have shown that MiRVs have little impact on the virological response to a raltegravir-based regimen.
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Methods
Study population and design
Sanger sequencing and UDS were performed on plasma samples at failure of 134 patients failing an INSTI-based regimen (65 failed under raltegravir, 20 under elvitegravir and 49 under dolutegravir), which were collected between January 2014 and March 2017 at Pitié-Salpêtrière, Saint-Antoine and Bichat hospitals, Paris, France. Patients were defined as having failure under an INSTI-based regimen if two consecutive viral loads were .50 copies/mL during treatment.
To evaluate the clinical impact of baseline MiRVs on INSTI response, we sequenced the integrase gene by UDS and compared the MiRV presence at baseline of patients having VF with those having virological success (VS) under INSTI treatment in the same period. For the VF group, of 134 patients failing INSTIs who were enrolled, we selected 34 patients whose samples were available prior to INSTI initiation. For the VS group, we selected 31 patients initiating a first-line INSTI-based regimen, with samples available prior to INSTI initiation and undetectable viral load (,50 copies/mL) for at least 6 consecutive months.
All patients signed an informed consent for the anonymous use of their clinical and biological data.
RNA extraction, PCR and Sanger sequencing
Samples had been previously sequenced in our laboratory during the clinical monitoring of patients. Briefly, 80 lL of HIV RNA was extracted from 1 mL of plasma (NucliSENS V R easyMAG V R , bioMérieux Clinical Diagnostics). The extracted RNA was reverse transcribed into cDNA and a fragment of the integrase gene (corresponding to amino acids 49-286) was amplified by PCR in a two-round process. The first round was performed with forward primer (4339-4359) 5 0 -TAG TAG CCA GCT GTG ATA AAT GTC-3 0 and reverse primer (5082-5102) 5 0 -TTC CAT GTT CTA ATC CTC ATC CTG-3 0 using a Transcriptor One
Step RT-PCR kit (Roche Life Science, Germany) following the manufacturer's protocol. PCR products were diluted to 1/10 and subjected to a nested round with forward primer (4374-4389) 5 0 -GAA GCC ATG CAT GGA CAA G-3 0 and reverse primer (5072-5090) 5 0 -ATC CTC ATC CTG TCT ACT TGC C-3 0 using the Q5 V R High-Fidelity PCR Kit (New England Biolabs, USA) following the manufacturer's protocol. The PCR products were purified by Sephadex gel and sequenced using the Sanger method (BigDye Terminator, Applied Biosystems, Foster City, CA, USA).
UDS and computational method
Integrase amplicons were deep-sequenced using the Illumina MiSeq platform. The nested PCR products were purified by SPRIselect beads (Beckman Coulter, France), 'tagmentated' (fragmented and tagged) and prepared for libraries using Nextera V R DNA Sample Preparation and Index Kit (Illumina, USA) according to the manufacturer's protocol. Resulting libraries were quantified on a 2100 Bioanalyzer (Agilent Technologies), normalized and pooled equimolarly. Pooling libraries were subjected to standard Illumina paired-end sequencing at 2%150 bp on the MiSeq platform.
UDS analyses were performed using a fully automated analysis pipeline commercially available via SmartGene (www.smartgene.com; SmartGene, Zug, Switzerland). Briefly, paired-end reads are merged and quality-filtered to remove noise. Alignment is performed using a target-specific profile and a consensus is produced based on a user-selected ambiguity threshold. Mutations are called by frame-aware alignment with reference sequence HXB2 (Los Alamos, accession number AF033819) above a user-selected threshold (range " 0.5%-30%) at a predetermined minimum coverage of reads.
Resistance interpretation
Interpretation of resistance was in accordance with the ANRS resistance algorithm version 27 (updated September 2017, www.hivfrenchresistance. org). Briefly, integrase gene mutations A49G, T66I/A/K, L74M/I, E92Q, T97A, G118R, F121Y, E138A/K/T, G140A/C/S, Y143A/C/G/H/R/S, P145S, S147G, Q148E/G/H/K/R, V151L, S153Y/F, N155H/S/T, E157Q, S230G/R and R263K were analysed.
Mutational load was calculated based on the frequency of mutations detected by UDS and plasma viral load. Mutations were defined as majority if they accounted for 20% of viral population and were detected by both techniques, and as minority if they accounted for ,20% of viral population and were detected only by UDS.
The susceptibility of virus at baseline to ARVs received including INSTIs was evaluated by calculating the genotypic susceptibility score (GSS) based on Sanger genotypic resistance test results at baseline. Results of 'susceptible', 'possible resistance' and 'resistance' to an ARV were interpreted into scores of 1, 0.5 and 0, respectively. We classified patients into two groups: those with baseline GSS equal to 1 or 1.5 (considered as functional INSTI monotherapy) and those with GSS of 2.
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ARV plasma concentration measurement
To evaluate each patient's adherence to ART, trough plasma concentrations of INSTI (C trough at 12 or 24 h) were determined using ultraperformance LC coupled with tandem MS (Acquity UPLC/TQ24H, Waters Corp., Milford, MA, USA) as described previously. 23 INSTI plasma concentrations were interpreted according to the respective in vitro protein-adjusted IC 95 for WT HIV-1 (raltegravir, 15 ng/mL; 24 elvitegravir, 45 ng/mL 25 ) and according to the pharmacokinetic/pharmacodynamic relationship of the SAILING trial 26 (dolutegravir, 1000 ng/mL).
Results
Patient characteristics
Of 134 patients failing an INSTI-based regimen, 65, 20 and 49 patients failed raltegravir-, elvitegravir-and dolutegravir-based regimens, respectively. Patient characteristics are described in Table 1 . Viruses at baseline of 34 patients with VF were compared with those of 31 patients with VS under INSTI treatment. Significant differences between both groups were observed for gender, viral load at baseline, nadir CD4 and use of NRTI class in association with INSTIs. Patient characteristics are shown in Table 2 .
Read coverage and technical validation of UDS
A median of 62250 reads per amplicon (IQR " 55147-100483) was obtained. The cellular clone 8E5, harbouring a single HIV provirus, was also amplified and sequenced following the same procedure as a control for error rate. The mean + SD of error rate per bp (%) was 0.004+0.0766. The maximal error rate obtained at one nucleotide position was 1.6% but was only observed once in the 5 0 extremity where the reads coverage diminished significantly, far fewer than 5000 reads. Few data are available regarding the threshold to interpret the impact of MiRVs in a clinical context. Therefore, thresholds of 1% and 5% with a minimum coverage of 5000 reads at one nucleotide position were used to retain MiRVs for resistance interpretation.
Sanger sequences were submitted to GenBank with accession numbers MH143121-MH143242 and UDS sequences were submitted to GenBank with accession number SRP137063.
INSTI plasma concentration results
INSTI plasma concentrations at time of treatment failure were available for 102/134 patients. Eighty-five patients (79.4%) had an effective C trough of the INSTIs used, while 6 (5.6%) and 11 (10.2%) patients had low level and undetectable levels of the INSTIs used, respectively. The median (IQR) C trough values for raltegravir q12h, dolutegravir q24h, dolutegravir q12h and elvitegravir/cobicistat on available dosage results were 107 (53.5-500), 1868 (1310-2877), 2002 (787-3171) and 472 (258-826) ng/mL, respectively ( Figure 1 ).
GSS at baseline based on Sanger genotypic resistance test results
Sanger genotypic resistance test results were available for 130/134 patients failing INSTI-based regimens. Thirteen patients (10%) had a total GSS at baseline of 1 or 1.5, while 117 patients (90%) had a GSS of 2 (44/130, 33.8%) or .2 (73/130, 56.2%).
Prevalence of majority resistant variants (MaRVs) at failure detected by both Sanger sequencing and UDS techniques
Overall, viruses harboured no MaRVs and were then considered as fully susceptible to all INSTIs in 60.4% cases (n " 81/134). INSTI C trough measurement was available for 60 of them. Fifty of these 60 patients (83.3%) had an effective C trough of the INSTIs used, while 4 (6.7%) and 6 (10.0%) patients had a low level and an undetectable level of the INSTIs used, respectively. C trough measurement was available for 42 of 51 patients whose virus was resistant genotypically to at least one INSTI. Effective, low-level and undetectable C trough values were determined in 34 (81.0%), 3 (7.1%) and 5 (11.9%) patients, respectively.
Genotypically, viruses of 35.8% (n " 48), 38.8% (n " 52), 24.6% (n " 33) and 4.5% (n " 6) of patients were considered to be resistant to raltegravir, elvitegravir, dolutegravir q24h and dolutegravir q12h, respectively. Regarding INSTI mutation patterns, among MiRVs in patients failing an integrase inhibitor-based regimen JAC 53 patients detected at failure with at least one MaRV, the most dominant pathways of resistance are N155H and Q148H/K/R, which were observed in 24 (45.2%) and 12 (22.6%) patients, respectively, whereas Y143C was detected in 6 (11.3%) patients. The other INSTI mutations detected were T66A/K/I (n " 3), L74M/I (n " 12), E92Q (n " 6), T97A (n " 10), E138A/K (n " 4), G140A/C/S (n " 7), S147G (n " 4), S153Y (n " 1) and E157Q (n " 3). Q148H/K/R was accompanied by G140A/C/S in 7 cases among the 12 patients harbouring this resistance profile. No patients had the R263K mutation.
No statistical difference was observed in the prevalence of MaRVs at failure in INSTI-naive and -experienced patients (37.8% and 43.2%, respectively; P " 0.729).
Prevalence of MiRVs at failure additionally detected by UDS UDS additionally detected MiRVs in viruses of 9% (12/134) of patients at the 5% threshold and in 18% (24/134) of patients at the 1% threshold. Among those 24 patients, 13, 3 and 8 failed a raltegravir-, a dolutegravir-and an elvitegravir-based regimen, respectively. Ten out of the 24 patients were previously treated with an INSTI-based regimen.
Considering the 1% threshold, among the 13 patients failing a raltegravir-based regimen (6 were INSTI-experienced patients), we detected the presence of MiRVs at failure, including T66A/I (3/13), E92Q (3/13), T97A (3/13), E138A/K (4/13), G140S (1/13), Y143C (2/13), S147G (1/13), N155H (3/13) and S230G (1/13). In Nguyen et al. particular, the virus of one patient carried mutations E92Q at 21.5% and N155H at 25.7%, which were detected only by UDS.
Among the three patients failing an elvitegravir-based regimen, R263K was detected at a non-negligible frequency (7.9% and 20.4%) in viruses of two patients who were previously treated with raltegravir. Furthermore, in the virus of another patient naive to INSTI treatment, S230R was additionally detected by UDS at 41%, which was in association with the major mutation N155H found at 100% by both techniques.
Four out of eight patients failing a dolutegravir-based regimen were previously treated with a raltegravir-containing regimen. Only two among them harboured viruses carrying MaRVs detected by both techniques, such as E138K, G140S and Q148H. UDS additionally detected the T66A as MiRVs in these two patients. Six out of 8 patients' viruses (75%) carried solely MiRVs detected by UDS at failure, such as T66A/I (2/6), Y143C/H (2/6), S147G (1/6), Q148R (2/6) and S153F (1/6).
No MiRVs detected by UDS at frequencies of 20% were identifiable from the Sanger sequencing chromatograms even as background noise.
Overall, the presence of MiRVs led to changes in resistance interpretation of the INSTI class in 13% (17/134) of patients when taking into account mutations at the 1% threshold and in 7% (10/134) of patients at the 5% threshold.
No statistical difference was observed in the prevalence of MiRVs at failure in INSTI-naive and -experienced patients (55.6% and 61.3%, respectively; P " 0.527).
To verify if these MiRVs existed prior to treatment or were selected under treatment pressure, we were able to sequence viruses at baseline of 10/24 patients who carried MiRVs at failure; this sequencing was not possible for the 14 other patients due to the absence of samples or low viral load prior to INSTI treatment. Finally, no MiRVs were detected in viruses at baseline of the 10 patients for whom viral sequences were obtained. MiRVs and MaRVs at failure are shown in Table S1 (available as Supplementary data at JAC Online).
Presence of MiRVs at baseline in patients with VF and in those with VS
To further evaluate the impact of MiRVs on response to INSTI treatment, samples at baseline of patients with VF (n " 34) and those with VS (n " 31) were sequenced by UDS. No MaRVs were detected at baseline in either group. Among the 34 patients failing INSTI treatment, 17 (50%) harboured at failure viruses carrying INSTI MaRVs. We detected MiRVs in 5/34 (14.7%) viruses at baseline, but none of these mutations was detected either as majority or minority mutations at failure. Regarding the 31 patients who achieved VS under INSTI treatment, MiRVs were found at baseline in viruses of 4 (12.9%) patients, with one in particular harbouring Q148H at 13.1%. Statistical analysis showed no difference between both groups in terms of presence of MiRVs at baseline (P " 0.817). Detected mutations and clinical data of patients are presented in Tables 3 and 4 .
Discussion
In this study, we analysed the prevalence and impact of INSTIresistant variants on treatment outcome by a sensitive technique, UDS, compared with Sanger sequencing. In accordance with results from other studies, we detected by both techniques the presence of INSTI MaRVs at failure in only 39.6% of INSTI nonresponders. Indeed, Fourati et al. 13 found the same prevalence (39%) of resistant variants in their study of 502 patients failing a raltegravir-based regimen. Moreover, both studies concluded that, when resistant variants were detected, the most dominant resistant pathways evidenced were N155H and Q148H/K/R. 13 In this study, the INSTI plasma concentration measurement results available (102/134 patients) showed good adherence to ART in 79% of patients. No difference in patient adherence was observed between patients whose viruses carried at least one INSTI MaRV and those without an MaRV. Effective INSTI C trough values in the former and the latter were 83% and 81%, respectively. To explore other factors, such as mutations in the reverse transcriptase and protease at baseline inducing resistance to associated drugs, we evaluated the susceptibility of virus at baseline to ARVs received by calculating the GSS. We found that only 10% of patients had a total GSS of 1-1.5, while 90% of patients had a total GSS of 2 (33.8%) or .2 (56.2%). This suggests that patients were treated with a solid backbone of ARVs and therefore resistance to other drug classes at baseline could not explain failure of the INSTIbased regimen. Therefore, in addition to drug resistance testing and adherence follow-up, other factors might be considered should an INSTI-based regimen fail. A recent in vitro study by Malet et al. 27 has interestingly described a new mechanism of resistance to INSTI with the emergence of mutations located in the nef region of the virus.
To understand and better explain therapeutic failure to INSTIbased regimen, we investigated by UDS the prevalence at failure of MiRVs in 134 INSTI non-responders. We additionally detected the presence of MiRVs in 24/134 viruses (18%) at the 1% threshold, leading to changes in INSTI resistance interpretation in 17 patients. The resistance mutations detected most frequently only by UDS were T66A/I (7/24, 29.2%), E92Q and E138A/K (both at 4/24, 16.7%), T97A, Y143C and N155H (all at 3/24, 12.5%), and S230G and R263K (both at 2/24, 8.3%). Interestingly, R263K, which was reported to be selected in vitro by elvitegravir, 28, 29 was detected by UDS at a non-negligible frequency (7.9% and 20.4%) in viruses of two patients failing an elvitegravir-based regimen.
It should be noted that several mutations present at frequencies .20% but only detected by UDS have been described previously 30, 31 but the contrary is rarely reported. In this study, one mutation (E92Q) was detected by UDS at 11% but was also detected by Sanger sequencing. This may be explained either by sequencing technique or PCR bias. In our study, some low viral loads (,1000 copies/mL) may have led to possible PCR bias and hence inaccurate quantification by UDS. However, a more important question here is whether MiRVs at any frequency could, given INSTI selection pressure, turn into MaRVs and therefore contribute to INSTI VF.
In fact, several studies have tried to answer this question but the clinical significance of INSTI MiRVs is still debated. 18, [32] [33] [34] To the best of our knowledge, few studies have conclusively established the relationship between the presence of integrase gene MiRVs and the risk of failure under INSTI treatment. A study by Charpentier et al. 18 using UDS at a detection threshold of 1% reported a prevalence of 9% of raltegravir-resistant variants at baseline but no association with VF was established. Another study MiRVs in patients failing an integrase inhibitor-based regimen JAC by Charpentier et al. 34 using UDS on 27 patients receiving dolutegravir plus lamivudine treatment showed that 26% of patients harboured INSTI MiRVs in baseline DNA genotypes, although all maintained virological suppression. To better characterize this association, we used UDS to search for the presence at baseline of integrase gene MiRVs in patients with VF and in those with VS receiving INSTI treatment. We found that MiRVs at baseline were present in both groups with similar prevalence (14.7% versus 12.9% in treatment failure and treatment success groups, respectively). Moreover, MiRVs detected at baseline in 5/34 patients failing an INSTI-based regimen were not found at failure as either majority or minority mutations regardless of selection of other MaRVs at failure. These results suggest that the presence of INSTI MiRVs at baseline might not be associated with risk of VF in patients receiving INSTI treatment. However, the clinical significance of MiRVs at baseline is somehow still questionable because the presence of certain pre-existing MiRVs could probably facilitate selection of other MaRVs at failure, although the mechanism for this has not been demonstrated. Moreover, if switching to other INSTIs is considered after failure to an INSTI, the presence of MiRVs at failure could be important for choice of switch especially if patients are not treated with a fully active backbone or if their virus replicates for a long time under INSTI treatment. This study has some limitations. We determined the detection threshold of UDS based on an external control, the cellular clone 8E5 harbouring a provirus instead of a viral RNA template. The error rate could be higher than measured if the reverse transcription step is taken into account and if samples are of low viral load creating insufficient templates for sequencing. However, the two rounds of PCR were performed with highly effective and high-fidelity enzymes, which are expected to induce a very low error rate as described elsewhere (,1%). 35, 36 Nevertheless, based on this limitation, two thresholds (1% and 5%) of MiRV detection were presented in this study.
Another limitation in this study was the low number of patients selected in the two groups of patients with VF and VS, making it difficult to draw a robust conclusion about the clinical impact of baseline MiRVs. Importantly, to ensure that MiRVs detected in patients with VS would not be affected by previous exposures to ARVs or INSTIs, we included only those initiating their first-line ART via an INSTI-based regimen. Several differences were observed in the two groups of patients, but these were coherent with our selection criteria. The same prevalence of baseline MiRVs detected in patients with VS compared with those with VF can therefore be presumed to enhance our conclusion about the small impact of baseline MiRVs on INSTI response. Nguyen et al.
In conclusion, the present study showed a prevalence of 39.6% of INSTI-resistant variants by Sanger sequencing and 57.5% by UDS at the 1% threshold among 134 patients failing an INSTIcontaining regimen, without significant impact on the virological outcome of an INSTI-based regimen containing raltegravir, elvitegravir or dolutegravir.
